When a client's core product line faces regulatory disruption or market headwinds, pet products represent a structurally attractive diversification target. The pet market is large, stable, and — critically — insulated from many of the regulatory pressures that affect human consumables (particularly in the hemp, THC, and supplement categories). This makes it a viable near-term revenue channel for extraction and formulation companies that already possess relevant manufacturing capabilities.
This insight surfaced during a strategic pivot discussion with [1], whose hemp-derived THC business was disrupted by federal regulatory changes. Asymmetric proposed pet products as one of three immediate pivot options precisely because the client's existing extraction capabilities transferred directly to the category with no new compliance burden.
Supply white-label or ingredient-level product to established pet brands that want to incorporate functional extracts (CBD, mushroom, etc.) into their existing product lines.
Advantages:
- Fastest path to revenue — no brand development required
- Leverages existing sales relationships and manufacturing credibility
- Lower marketing spend; relationship-driven sales motion
- Validates product-market fit before committing to a proprietary brand
Considerations:
- Margin compression — B2B pricing is typically lower than DTC
- Dependency on the partner brand's distribution and marketing success
- Limited brand equity accrues to the supplier
Develop and market a branded pet product line directly to consumers or through retail channels.
Advantages:
- Higher margin potential over time
- Builds durable brand equity and customer relationships
- Full control over positioning, pricing, and product roadmap
Considerations:
- Longer time to meaningful revenue — brand awareness takes time and investment
- Requires marketing infrastructure (creative, paid media, content, email)
- Competitive pet supplement market requires differentiated positioning
For clients in a cash-conservation or strategic-pause mode, the B2B supply approach should be pursued first. It generates revenue with existing capabilities and minimal incremental spend, while the proprietary brand option is developed in parallel as a longer-term play.
"There's really two angles there. One is to find pet brands that would like to use your product under their brand. And the second would be to create our own brand and push those products under that brand."
— Mark Hope, Asymmetric (American Extractions strategic pause call)
This framework applies most directly to clients who: